His primary areas of study are Immunology, Immunotherapy, Immune system, Cancer research and Cancer immunotherapy. His Immunology research includes elements of Cytotoxic T cell, Internal medicine and Cell culture. His Immunotherapy study combines topics from a wide range of disciplines, such as T cell, Immunity and Vaccination.
His Immune system research incorporates elements of Lymphocyte, Receptor, Antibody and Antigen. His Cancer research research is multidisciplinary, relying on both CD86 and Interleukin 8. Cancer covers Ignacio Melero research in Cancer immunotherapy.
His primary areas of investigation include Immunology, Immunotherapy, Cancer research, Immune system and Internal medicine. Ignacio Melero has researched Immunology in several fields, including Interleukin 12 and Genetic enhancement. He studies Cancer immunotherapy, a branch of Immunotherapy.
His Cancer research research includes themes of Immunogenic cell death, Cytotoxic T cell, Cell culture and CD8. The Immune system study combines topics in areas such as Antibody and CD40. His work on Nivolumab, Hepatocellular carcinoma and Sorafenib as part of general Internal medicine study is frequently connected to In patient, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them.
Ignacio Melero focuses on Cancer research, Immunotherapy, Immune system, Internal medicine and Cancer immunotherapy. His Cancer research study combines topics in areas such as Cytotoxic T cell, CD8, Antigen and Monoclonal antibody. Immunotherapy is a primary field of his research addressed under Immunology.
In the subject of general Immune system, his work in Immunity is often linked to Attenuated vaccine, thereby combining diverse domains of study. His Internal medicine research focuses on Oncology and how it relates to Atezolizumab, Chemotherapy, Inflammation and Phases of clinical research. His work deals with themes such as T cell, Adoptive cell transfer, Chimeric antigen receptor, Receptor and Interleukin 12, which intersect with Cancer immunotherapy.
Ignacio Melero mostly deals with Cancer research, Immune system, Immunotherapy, Cancer immunotherapy and Cancer. His Cancer research study incorporates themes from Immune checkpoint, CD137, Cytotoxic T cell, Monoclonal antibody and Immunogenic cell death. Ignacio Melero does research in Immune system, focusing on Tumor microenvironment specifically.
His Immunotherapy research incorporates themes from Colitis, Radioimmunotherapy, Melanoma, Lung cancer and Radiation therapy. His Cancer immunotherapy research is multidisciplinary, relying on both T cell, CTLA-4, Chimeric antigen receptor, Adoptive cell transfer and Antigen. The subject of his Antigen research is within the realm of Immunology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry;Bruno Sangro;Thomas Yau;Todd S. Crocenzi.
The Lancet (2017)
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.
Bruno Sangro;Carlos Gomez-Martin;Manuel de la Mata;Mercedes Iñarrairaegui.
Journal of Hepatology (2013)
Therapeutic vaccines for cancer: an overview of clinical trials
Ignacio Melero;Gustav Gaudernack;Winald Gerritsen;Christoph Huber.
Nature Reviews Clinical Oncology (2014)
Phase I Trial of Intratumoral Injection of an Adenovirus Encoding Interleukin-12 for Advanced Digestive Tumors
Bruno Sangro;Guillermo Mazzolini;Juan Ruiz;Maite Herraiz.
Journal of Clinical Oncology (2004)
Evolving synergistic combinations of targeted immunotherapies to combat cancer.
Ignacio Melero;David M. Berman;M. Angela Aznar;Alan J. Korman.
Nature Reviews Cancer (2015)
Direct Effects of Type I Interferons on Cells of the Immune System
Sandra Hervas-Stubbs;Jose Luis Perez-Gracia;Ana Rouzaut;Miguel Fernandez de Sanmamed.
Clinical Cancer Research (2011)
Immunological landscape and immunotherapy of hepatocellular carcinoma
Jesús Prieto;Ignacio Melero;Bruno Sangro.
Nature Reviews Gastroenterology & Hepatology (2015)
Classification of current anticancer immunotherapies
Lorenzo Galluzzi;Erika Vacchelli;José Manuel Bravo-San Pedro;Aitziber Buqué.
CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells with IFN-γ-Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination
Noelia Casares;Laura Arribillaga;Pablo Sarobe;Javier Dotor.
Journal of Immunology (2003)
Dendritic cells in cancer immunology and immunotherapy.
Stefanie K Wculek;Francisco J Cueto;Adriana M Mujal;Adriana M Mujal;Ignacio Melero.
Nature Reviews Immunology (2020)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: